Asia-Pacific Anti-inflammatory Therapeutics Market to Reach $40.5 Billion by 2032 With CAGR of 5.4%: Says Allied Market Research
Increase in number of people suffering from inflammatory diseases, surge in use of anti-inflammatory therapeutics, and strong product pipeline drive the growth of the Asia-Pacific anti-inflammatory therapeutics market.
Wilmington, Delaware, Nov. 05, 2023 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, “Asia-Pacific Anti-inflammatory Therapeutics Market, By Drug Class (Biologics, NSAIDs, Corticosteroids, and Others), By Indication (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, and Inflammatory Bowel Disease, and Others) By Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2022-2032.” According to the report, the Asia-Pacific anti-inflammatory therapeutics industry was estimated at $23.8 billion in 2022, and is anticipated to hit $40.5 billion by 2032, registering a CAGR of 5.4% from 2023 to 2033.
Request Sample of the Report on Asia-Pacific Anti-inflammatory Therapeutics Market Forecast 2032 – https://www.alliedmarketresearch.com/request-sample/1175
Prime determinants of growth
Increase in the prevalence of inflammatory diseases such as arthritis, inflammatory bowel diseases and others and surge use of corticosteroids to treat various inflammatory diseases drive the growth of the Asia-Pacific anti-inflammatory therapeutics market. However, side effects associated with the corticosteroids and NSAIDs are hampering the Asia-Pacific anti-inflammatory therapeutics market growth. On the contrary, increase in research and development activities for the development of novel anti-inflammatory therapeutics is expected to offer remunerative opportunity for expansion of the Asia-Pacific anti-inflammatory therapeutics market during the forecast period.
Report Coverage & Details:
|Market Size in 2022||$23.8 billion|
|Market Size in 2032||$40.5 billion|
|No. of Pages in Report||202|
|Segments covered||Drug Class, Indication, Distribution Channel, and Country.|
|Drivers||Surge in prevalence of inflammatory diseases
Strong availability of biologic drugs
|Opportunity||New drugs in pipeline|
|Restraint||Side-effects associated with anti-inflammatory drugs|
- In the economic recession, the anti-inflammatory therapeutics market is driven by increase in prevalence of inflammatory diseases.
- However, fluctuations in the demand for pharmaceuticals including anti-inflammatory therapeutics as companies adjust their spending priorities impact the anti-inflammatory therapeutics market growth.
Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/1175
The biologics segment to maintain its leadership status throughout the forecast period
Based on drug class, the biologics segment held the highest market share in 2022, and is the fastest growing segment during the forecast period, accounting for more than two-fifths of the anti-inflammatory therapeutics market revenue, owing to increase in use of biologics for the treatment of arthritis and other inflammatory diseases.
The arthritis segment to maintain its lead position during the forecast period
Based on indication, the arthritis segment accounted for the largest share in 2022, and is the fastest growing segment during the forecast period, contributing to nearly two-fifths of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to, increase in prevalence of arthritis and surge in number of people taking treatment for arthritis.
The drug stores and retail pharmacies segment to maintain its leadership status throughout the forecast period
Based on distribution channel, the drug stores and retail pharmacies segment held the highest market share in 2022, and is the fastest growing segment during the forecast period, accounting for nearly two-fifths of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to increase in sell of anti-inflammatory drugs through retail pharmacy stores and rise in number of people suffering from various inflammatory diseases.
China to maintain its dominance by 2032
Based on country, China held the highest market share in terms of revenue in 2022, accounting for more than one-fourth of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to development of healthcare infrastructure and high disease population in this country. However, Japan is expected to witness the fastest CAGR of 6.1% from 2023 to 2032, owing to strong presence of market key players and increase in product new product launches in this country.
For Procurement Information – https://www.alliedmarketresearch.com/purchase-enquiry/1175
Leading Market Players: –
- Abbvie Inc.
- Amgen Inc.
- Pfizer Inc.
- GalaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Johnson and Johnson
- Novartis AG
- Eli Lilly and Company
- Bayer AG
- AstraZeneca plc
The report provides a detailed analysis of these key players of the Asia-Pacific anti-inflammatory therapeutics market. These players have adopted strategies such as, product launch and product approval to increase their market share and maintain dominant shares in different countries. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Comprehensive Healthcare Industry Research Studies: –
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.